🇺🇸 FDA
Patent

US 9475880

Anti-CD134 (OX40) antibodies and uses thereof

granted A61PA61P35/00A61P35/02

Quick answer

US patent 9475880 (Anti-CD134 (OX40) antibodies and uses thereof) held by Biocerox Products B.V. expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Biocerox Products B.V.
Grant date
Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P35/00, A61P35/02, A61P35/04, A61P37/04